by qfrsolutions | Mar 27, 2017 | News
Source: FierceBiotech Allergan and partner Paratek Pharmaceuticals have hit their primary endpoints in two key phase 3 acne trials for their investigational med sarecycline. The pair will now seek an FDA NDA in the second half of the year after the two...
by qfrsolutions | Mar 21, 2017 | News
Source: Cipher Pharmaceuticals Inc. (CPH.TO) (“Cipher” or “the Company”) announced today that veteran pharmaceutical industry executive Robert D. Tessarolo has been appointed President and Chief Executive Officer of Cipher, effective April 17 ,...
by qfrsolutions | Mar 17, 2017 | News
Source: Sun Pharmaceutical Industries today said an indirect arm of its group firm Taro will fully acquire Canada’s Thallion Pharmaceuticals for 2.7 million Canadian dollar. Taro Pharmaceuticals Inc (Canada) has entered into an agreement to acquire all of the...
by qfrsolutions | Mar 6, 2017 | News
Source: Novan MORRISVILLE, N.C., March 06, 2017 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that, after further analysis of the results from the NI-AC301 and NI-AC302 pivotal clinical trials for the Company’s topical...
by qfrsolutions | Feb 13, 2017 | News
Source: Since its massive Pfizer merger fell through last year, Allergan has persisted with “stepping-stone deals” rather than a transformational buy. Monday, the drugmaker unveiled its latest buy, Zeltiq, a $2.47 billion add-on for its aesthetics...
by qfrsolutions | Jan 27, 2017 | News
Source: Business Wire Encore Dermatology Inc., a privately held dermatology company that specializes in developing and commercializing novel prescription products for improving skin health, announced today the availability of TridesilonTM (desonide) Cream, 0.05% in a...
